Japan’s Eisai Gets Preliminary Injunction Against Teva Aricept Generic
This article was originally published in PharmAsia News
Executive Summary
Japan's Eisai has managed to halt Teva Pharmaceutical plans to market a generic of Eisai's Aricept (donepezil) for treating Alzheimer's disease. Eisai said a U.S. district court issued a preliminary injunction against Teva pending the outcome of a patent-infringement suit Eisai filed against the Israeli drug maker. Eisai, whose Aricept patent does not expire until 2010, said the request for the injunction was part of its effort to "protect our intellectual property throughout the world." (Click here for more